Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States.

Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States.

Publication date: Jan 12, 2024

Policymakers in the United States (US) recommend coronavirus disease 2019 (COVID-19) vaccination with a monovalent 2023-2024 vaccine formulation based on the Omicron XBB. 1.5 variant. We estimated the potential US population-level health and economic impacts of increased COVID-19 vaccine coverage that might be expected with the availability of a protein-based vaccine with simpler storage requirements in addition to messenger ribonucleic acid (mRNA) vaccines. A Markov model was developed to estimate 1-year COVID-19-related costs, cases, hospitalizations, and deaths with and without the availability of a protein-based vaccine option. The model population was stratified by age and risk status. Model inputs were sourced from published literature or derived from publicly available data. Our model estimated that a five-percentage-point increase in coverage due to the availability of a protein-based vaccine option would prevent over 500,000 cases, 66,000 hospitalizations, and 3000 COVID-19-related deaths. These clinical outcomes translated to 42,000 quality-adjusted life years (QALYs) gained and an incremental cost-effectiveness ratio of USD 16,141/QALY from a third-party payer perspective. In sensitivity analyses, outcomes were most sensitive to COVID-19 incidence and severity across age groups. The availability of a protein-based vaccine option in the US could reduce hospitalizations and deaths and is predicted to be cost-effective.

Open Access PDF

Concepts Keywords
Coronavirus COVID-19
Hospitalizations economic analysis
Party population health
vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination coverage
disease VO population
disease VO vaccination
disease VO vaccine
disease VO COVID-19 vaccine
disease VO storage
disease IDO quality
disease VO effectiveness
disease VO effective
disease VO USA
drug DRUGBANK Coenzyme M
disease VO organization
disease VO vaccinated
disease MESH emergency
disease MESH uncertainty
disease MESH vaccine preventable diseases
disease VO vaccine effectiveness
disease VO immunization
disease IDO history
disease VO primary vaccination
disease MESH chronic diseases
disease MESH long COVID
disease MESH death
disease MESH infection
disease MESH causes
disease VO monthly
disease VO dose
disease VO vaccine dose
disease VO Comirnaty
disease VO vaccine storage
disease IDO intervention
disease IDO virulence
disease MESH infectious diseases
disease MESH influenza
disease VO Viruses
disease VO time
drug DRUGBANK Spinosad
disease VO unvaccinated
drug DRUGBANK L-Phenylalanine
pathway REACTOME Release
drug DRUGBANK Tropicamide
drug DRUGBANK Vorinostat
disease VO report
disease VO Optaflu
disease VO influenza vaccines
disease MESH sequelae

Original Article

(Visited 1 times, 1 visits today)